jobs.jnj.com/en/jobs/
Skip to content
✕
Internet Explorer is no longer supported by this website.
For optimal browsing we recommend using
Chrome
,
Firefox
or
Safari
.
Home Link (JNJ Logo)
Home Link (JNJ Logo)
Home Link (JNJ Logo)
Home Link (JNJ Logo)
Menu
Search
Toggle Menu
Change Country
Our Stories
Latest News
Innovation
Caring & Giving
Personal Stories
Health & Wellness
Our Heritage
Our Company
About J&J
Our Credo
Our Leadership Team
Code of Business Conduct
Corporate Reports
Diversity, Equity & Inclusion
ESG Policies & Positions
Innovation at J&J
Digital Solutions
J&J Health and Wellness Solutions
Office of the Chief Medical Officer
Veterans, Military & Military Families
Products
MedTech
Pharmaceutical Products
Suppliers
Responsible Supply Base
Supplier-Enabled Innovation
Supplier Resources
Careers
Life at J&J
Diversity, Equity and Inclusion
Career Areas of Impact
Students
Re-Ignite Program
Contract & Freelance Partner Opportunities
Career Stories
Media Center
Investors
2023 Annual Meeting of Shareholders
Corporate Governance
Quarterly Results
SEC Filings
News Releases
Pharmaceutical Pipeline
2022 Janssen Transparency Report
2021 Health for Humanity Report
ESG Investor Update
ESG Resources
Stock Information
Webcasts & Presentations
Investor Fact Sheet
Our Societal Impact
Global Community Impact
Global Public Health
Global Environmental Sustainability
Close Countries Menu
Explore more Johnson & Johnson sites:
China
France
Germany
India
Japan
Russia
Switzerland
German
English
French
United Kingdom
United States
Close Search Menu
Search input
Share
News and Updates
Our Company
September 13, 2022
Global Fund Private Sector Partners Pledge Record Levels of Support to End AIDS, TB, Malaria and Strengthen Systems for Health
Innovation
August 17, 2022
PAN-TB Collaboration to Advance Investigational Tuberculosis Drug Regimens to Phase 2 Clinical Trials
Innovation
June 21, 2022
Groundbreaking Data-Sharing Initiative Launches to Increase Understanding of Antimicrobial Resistance
Innovation
May 11, 2022
“DOST” Model to Link and Support Drug Resistant TB Patients From Private Sector: An Experience From Delhi, India
Innovation
March 24, 2022
“We Want a World Without Tuberculosis in Our Lifetimes”
Our Company
March 24, 2022
Johnson & Johnson Announces Series of Youth Initiatives Aimed at Helping to Empower a Generation to End Tuberculosis
Our Company
March 24, 2022
Empowering a Generation of Youth to End TB
Our Company
January 02, 2022
Taking action on AMR: Largest life sciences sector coalition shows leadership in R&D, appropriate use and access to antibiotics and responsible manufacturing
Our Company
December 14, 2021
Regional tuberculosis forum shines spotlight on innovation and collaboration driving progress toward ending tuberculosis in Asia Pacific
Our Company
December 10, 2021
Best Practices in Private Sector engagement to advance the fight against T
Our Company
November 19, 2021
Reaching Children with TB Care
Our Company
November 18, 2021
Johnson & Johnson is Proud to Lead Efforts to Outpace Antimicrobial Resistance
Our Company
November 12, 2021
Adapting Covid-19 Innovations to Accelerate Progress toward Meeting Global Tuberculosis Goals
Innovation
October 20, 2021
Collaborating to Speed Up Innovation
Innovation
July 15, 2021
UNITE4TB fires up its engine in the race to develop new TB treatment regimens
Our Company
July 09, 2021
Johnson & Johnson Launches Network of Global Health Discovery Centers that Aim to Speed Up Science and Tackle Pandemic Threats
Innovation
March 24, 2021
Building Resilient Health Systems Through Further Investments in TB
Our Company
March 24, 2021
Johnson & Johnson Announces Five Initiatives to Help Find the ‘Missing Millions’ of Undiagnosed People Living with Tuberculosis
Innovation
March 24, 2021
2 Pandemics, 1 Goal: Meet 4 Innovators with High-Tech Ideas for Fighting Tuberculosis in the Time of COVID-19
Innovation
March 24, 2021
As 2030 Deadline Looms We Must Accelerate Progress Against TB
Innovation
March 23, 2021
Advancing the Future of Tuberculosis (TB) Treatment
Innovation
January 26, 2021
2021 Access to Medicine Index
Innovation
December 10, 2020
3 Ways Johnson & Johnson Is Innovating to Help Fight Tuberculosis
Our Company
July 09, 2020
Statement attributed to Paul Stoffels on the occasion of the launch of the AMR Action Fund
Innovation
July 06, 2020
Stop TB Partnership and Johnson & Johnson, with support from USAID and The Global Fund, Announce Price Reduction for SIRTURO
®
(bedaquiline) for Treatment of Drug-Resistant Tuberculosis in Low- and Middle-Income Countries
Innovation
May 27, 2020
U.S. FDA Approves New Pediatric Formulation of SIRTURO
®
(bedaquiline) as Part of Combination Therapy to Treat Children with Pulmonary Multidrug-Resistant Tuberculosis
Innovation
May 27, 2020
J&J Launches Quickfire Challenge to Support Continuity of Care for DR-TB Patients During COVID-19
Our Company
March 24, 2020
Statement on the Occasion of World Tuberculosis Day
Innovation
February 27, 2020
First-of-Its-Kind Global Collaboration Launched to Develop Transformative Treatment Regimens for Tuberculosis
Our Company
January 24, 2020
How South Africa is spearheading efforts to tackle MDR TB
Our Company
January 23, 2020
Johnson & Johnson Recognized as Industry Leader in New AMR Benchmark
Our Company
January 22, 2020
Ending Tuberculosis is Good for Business: New Initiative Launched to Catalyze Action to End TB in the Workplace
Our Company
January 23, 2020
From Actor to Advocate: A New MTV Star Opens Up About the TB Epidemic
Innovation
January 16, 2020
Johnson & Johnson Collaborates with The MTV Staying Alive Foundation to Launch Youth-Focused “Edutainment” Campaign Focused on Tuberculosis & Other Health Issues in India
Innovation
December 16, 2019
World Health Organization Recommends the Use of Bedaquiline-Containing Treatment Regimens For All Drug-Resistant Tuberculosis Patients
Our Company
October 30, 2019
Johnson & Johnson Expands Efforts to Help End Tuberculosis in India
Our Company
October 04, 2019
Johnson & Johnson Commits $500 Million Investment Over Four Years to Help End the Epidemics of HIV and Tuberculosis
Global Public Health
August 14, 2019
Statement on U.S. FDA Approval of Pretomanid as Part of Bedaquiline-Containing “BPaL” Regimen
Innovation
August 09, 2019
Janssen Announces U.S. FDA Accelerated Approval for SIRTURO
®
(bedaquiline) as Part of Combination Therapy to Treat Adolescents with Pulmonary Multidrug-Resistant Tuberculosis
Innovation
July 23, 2019
Johnson & Johnson Establishes International Consortium to Advance Pioneering Science in the Fight to End Tuberculosis
Our Company
June 26, 2019
FACT SHEET: Safeguarding Bedaquiline for Drug-Resistant Tuberculosis (DR-TB) Treatment
Innovation
May 07, 2019
The Cost of Complacency: Economist Intelligence Unit Report Underscores Major Gaps in World’s Response to Drug-Resistant Tuberculosis
Our Company
May 07, 2019
INFOGRAPHIC: DR-TB—The Time to Act is Now
Our Company
February 13, 2019
Statement on Johnson & Johnson’s Commitment to TB in India
Innovation
September 25, 2018
The Quest to End Tuberculosis: 14 Memorable Moments in Innovation
Innovation
September 24, 2018
Johnson & Johnson Announces 10-year Initiative to Help End Tuberculosis, the World’s #1 Infectious Killer
Our Company
March 28, 2018
Breath for Life: The Johnson & Johnson Program That's Helping Eradicate Tuberculosis in Vietnam
Our Company
January 20, 2016
Johnson & Johnson Joins First Industry-wide Call for New Collective Action to Address Antimicrobial Resistance
Our Company
October 14, 2016
Telangana, Johnson & Johnson sign MoU to make state TB free
Our Company
September 12, 2014
Johnson & Johnson Announces New Grant to Harvard Medical School to Combat Drug-Resistant Tuberculosis
Innovation
June 16, 2009
Unique Collaboration Between TB Alliance And Tibotec to Accelerate Tuberculosis Drug Development
Back to top
You are now leaving jnj.com. The site you’re being redirected to is a branded pharmaceutical website. Please click below to continue to that site.
Continue
